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Objective. To develop a new composite disease activity score for gout and provide its first validation.
Methods. Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint
damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach
(factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS).
Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline
and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used.
Construct- and criterion-related validity were tested. External validation on an independent sample is reported.
Results. Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum
uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis
identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global
activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also
developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and dis-
crimination between patient- and physician-reported measures of active disease (construct validity). The results were
reproduced in the external sample.
Conclusion. This study developed and validated a composite measure of disease activity in gout. Further testing is
required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.
INTRODUCTION
Disease activity is a challenging concept in gout. Based on
the currently accepted model of the disease, high serum
levels of urate lead to joint deposits of uric acid crystals,
which may provoke acute arthritis. Acute inflammation
resolves but eventually evolves into chronic arthropathy,
with development of disability and impairment of quality
of life.
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An accurate measure of disease activity is an important
component of appropriate and targeted treatment strate-
gies, as well as of evaluation of new treatments.
Tissue deposits of uric acid (UA) are the best candidate
to measure disease activity in gout because they reflect a
still ongoing active disease process (1). Serum UA (sUA)
approximates tissue levels well, and it is the main target
of treatment in gout (2). The relevance of using sUA as the
outcome measure in gout is strengthened by the consider-
ation that drugs without influence on sUA do not have
any plausible effect on the disease process (3). Further-
more, sUA levels associate with the risk of acute arthritis
in a dose-dependent manner, and their persistent control
leads to a reduction of tissue deposits and risk of flare (4).
However, sUA is only weakly associated with other relevant
outcomes, such as disability and health-related quality of
life (HRQOL) in patients with gout (2).
Therefore, sUA is a necessary component of the measure-
ment of the activity of the disease process, but other com-
ponents might play a role (5). As recognized by Outcome
Measures in Rheumatology (OMERACT), several domains
should be assessed when evaluating the outcome of
patients with gout, some of them relating more to the cur-
rent disease activity, while others relate mainly to the con-
sequences of the disease (6). Interfering with sUA might not
be sufficient to control the activity of the disease process,
and to achieve this goal we need a feasible, reliable, and
valid measure to apply in practice and clinical trials.
An effective and more comprehensive way to describe
the activity of gout is to derive a composite measure of dis-
ease activity that includes and weights relevant variables,
such as sUA, joint inflammation, pain measures, and tophi
burden (5). Beyond its clinical (and statistical) relevance,
the main methodologic concerns rely on the face validity of
the items to be included, the assumption of a compensation
among items, and the relative response to treatment of
single items within the composite score (7). Previous stud-
ies explored the relative relevance of items belonging to the
OMERACT domains to be included in a composite outcome
measure, showing substantial disagreement among clini-
cians, researchers, and patients (5,8,9). Nevertheless, more
recently, a preliminary definition of remission has been pro-
posed, suggesting the potential validity of measuring a state
within the continuum of disease activity in gout (10).
This analysis aims to derive a new composite disease
activity score for gout and to provide its first validation.
For this purpose we applied a data-driven approach, ana-
lyzing data collected in a multicenter observational study,
including a random sample of gout patients with complete
baseline and followup clinimetric data. Candidate disease
activity scores were developed according to a well-
recognized data-driven process and externally validated.
PATIENTS AND METHODS
Study design, setting, and recruitment. This is a longi-
tudinal analysis of a multicenter cohort study (Kick-Off of
the Italian Network for Gout [KING] Study, promoted by
the Italian Society for Rheumatology [NCT01549210]),
including a nationwide representative sample of patients
referred to 30 rheumatology clinics across Italy, with a
clinical diagnosis of gout, recruited between June 2011
and January 2012 (see Appendix A for members of the
KING Study Group). A probability sample was drawn
from clinical registers as previously described, and clini-
cal diagnoses were validated by the participating rheuma-
tologists (11). All the patients were assessed at baseline, 6
months, and 12 months. The study protocol was approved
by the local ethics committees of the participating centers.
A validation sample of consecutive patients with crystal-
proven gout and acute symptoms was recruited between
September 2015 and November 2015 at 4 KING sites.
Variables. At baseline, 6 months, and 12 months all
patients underwent a full clinical evaluation that followed
a structured case report form, including both general
health and disease-specific variables.
Gout-related variables included symptoms duration,
classification according to the 1977 preliminary American
College of Rheumatology (ACR) criteria (12), disease-
related comorbidities, previous and current treatment for
gout, swollen and tender joint counts on 66 of 68 joints,
measurement of tophi (count and tape measure of all the
clinically evaluable tophi) (13), 0–10 on a visual analog
scale (VAS) for pain, patient’s global assessment of disease
activity (PtGA), general health and physician’s assessment
of response to treatment (PhGA), flare occurrence (patient-
reported acute and significant worsening of joint pain)
(14), and sUA levels. All patients completed the Italian
versions of the Health Assessment Questionnaire (HAQ),
the Short-Form 36 (SF-36) health survey, and the Gout
Impact Scale (GIS) (15–17). In the external validation sam-
ple, a patient acceptable symptom state (PASS) VAS (0–
100) was also measured along with variables to be included
in the activity scores and the HAQ.
The underlying construct of disease activity was
defined as the presence of tissue deposits leading to acute
or chronic inflammation and as a consequence to pain,
joint damage, and functional disability (see Supplementa-
ry Figure 1, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/
Significance & Innovations
 There are currently no composite disease activity
measures available for gout. This analysis pro-
vides a clinically useful instrument to define dis-
ease activity beyond the use of biomarkers as the
sole guidance for clinical decisions.
 Based on the results of this study, a composite
disease activity measure, including relevant
domains (serum urate levels, acute flares, tophus
burden, patient-reported outcomes) able to dis-
criminate between relevant states of disease, is
proposed.
 Further testing in different data sets is now
required to clarify the responsiveness and clini-
cal utility.
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acr.22844/abstract). As a consequence of this concept of
disease activity, the decision to change treatment at the
baseline visit (a new prescription or increasing dose/
switch of urate-lowering treatment not related to adverse
drug reactions, and/or prescription of symptomatic drugs,
such as colchicine, nonsteroidal antiinflammatory drugs,
or intraarticular/systemic glucocorticoids) or the occur-
rence of a gout flare within the following 6 months was set
as the criterion marker of disease activity to develop the
disease activity score.
For the purpose of these analyses, the included sample
size of .200 subjects is appropriate to develop response
criteria according to the recommendations of the ACR
Subcommittee on Classification and Response Criteria of
the ACR Committee on Quality Measures (18). Therefore,
a subsample of 214 patients from the study sample was
drawn for the development of the scores. For the purpose
of external validation, 60 subjects were deemed as suffi-
cient to detect correlation coefficients.0.35.
Selection of items and statistical methods. Starting
from a list of items belonging to the OMERACT domains
for studies on gout (6) (pain, sUA, joint swelling, joint ten-
derness, flare of gout, tophus burden, HRQOL, PhGA,
PtGA, functional disability, and work disability), 30 rheu-
matologists actively involved in the KING study were
asked to participate in a Delphi exercise to identify items
suitable to be included in a measurement of disease activi-
ty for gout.
After a brief introduction to the aim of the survey, par-
ticipants were asked to assign a 1–10 score of appropriate-
ness to each item to describe different constructs: disease
activity, disease-related damage, and general health. Invi-
tations to the second and third rounds were sent only to
participants who had completed the first round of the sur-
vey. Items were selected if more than 70% of the respond-
ers thought they were more suitable to describe disease
activity rather than damage or general health status, and
rejected if less than 30%. Items with an intermediate level
of agreement were proposed again in the second and third
rounds. Selected outcomes were then filtered based on
feasibility, reliability, and availability in the data set.
Two different methods to derive composite scores were
applied. A 3-step method followed the methodology
applied to other composite disease scores in rheumatic dis-
ease (19–21). Variables selected from the Delphi exercise
were standardized. A factor analysis was then applied, and
factors explaining more than 80% of the cumulative vari-
ance and eigenvalues .0.8 were retained. Factor loadings
were then fitted in a linear discriminant function analysis,
using the criterion of low/high disease activity as the classi-
fication rule. A classification table was used to evaluate the
misclassification rates of the model. Discriminant scores
were then computed for each subject and used as the depen-
dent variable of a multivariate hierarchical linear regression
analysis including transformed variables as regressors. The
combination of variables explaining more than 0.95 of varia-
tion of the discriminant score were selected to be included
in the final disease activity score for gout (Gout Activity
Score [GAS]). Finally, beta coefficients were normalized
and used to weight the transformed variables in order to
compute the GAS at every time point.
Given the low number of items to be evaluated in the
factor analysis that might have threatened the validity of
the 3-step approach, a second simplified method included
the a priori selected list of items in a discriminant func-
tion analysis. Discriminant coefficients were then normal-
ized and used to derive a second score. Internal validation
was performed by bootstrap (1,000 samples) and cross-
validation (20 samples) for the 3-step and the 1-step meth-
od, respectively.
GAS scores, developed in a training sample at baseline,
were then calculated on the overall study sample at base-
line, 6 months, and 12 months.
Criterion validity (concurrent and predictive) was tested
by comparing the GAS scores against the HAQ score, SF-
36 physical component summary and mental component
summary subscales by Spearman’s correlation coefficients
in the overall KING data set. A further internal validation
was performed evaluating the consistency of predictive
Table 1. Baseline patients’ characteristics*
Characteristic Value
Sex, no. males/total no. (%) 368/406 (90.6)
Age, mean6SD years 646 11.5
Current smokers, no./total no. (%) 68/405 (16.8)
BMI, mean6SD 28.06 3.9
Comorbidities, median (IQR) 3 (2–4)
Hypertension, no. (%) 287 (70.7)
Renal failure, no. (%) 47 (11.6)
Osteoarthritis, no. (%) 226 (55.7)
Cardiovascular disorders, no. (%) 105 (25.9)
Diabetes mellitus, no. (%) 58 (14.3)
Liver disorders, no. (%) 32 (7.9)
Neoplasms, no. (%) 25 (6.2)
Fulfills preliminary ACR criteria,
no./total no. (%)
373/405 (91.9)
Disease duration (years), median (IQR) 3.8 (1.6–10.2)
Joint involvement, no. (%)
Monoarticular (1 joint) 87 (21.4)
Oligoarticular (2–4 joints) 239 (58.9)
Polyarticular (.4 joints) 77 (19)
VAS pain (0–10), median (IQR) 2 (0–5)
VAS patient global (0–10), median (IQR) 1 (0–5)
Swollen joints (0–66), median (IQR) 0 (0–1)
Tender joints (0–68), median (IQR) 1 (0–3)
Presence of tophi, no. (%) 79 (19.5)
Tophi dimension, median (IQR) 1.5 (0.5–6.5)
Number of flares (3 months), median (IQR) 0 (0–0)
Flare (previous month), no. (%) 120 (29.6)
Serum urate level
Mean6SD mg/dl† 6.361.8
Mean6SD mmoles/liter 0.3760.11
Previous corticosteroids 117 (28.8)
Current NSAIDs or colchicine 172 (42.4)
Current allopurinol, no. (%) 279 (68.7)
Current febuxostat, no. (%) 55 (13.6)
* BMI5 body mass index; IQR5 interquartile range; ACR5
American College of Rheumatology; VAS5visual analog scale;
NSAIDs5nonsteroidal antiinflammatory drugs.
† Cutoff is 7 mg/dl.
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validity at different time points (e.g., prediction of HAQ
from baseline to 6 months and from 6 months to 12
months).
Construct (discriminant validity) was tested computing
the standardized mean difference (21) against the decision
to change treatment, categorized physician VAS of
response to treatment, and patient’s perception of being in
remission, as coded in the GIS (17).
In order to increase applicability to other existing data
sets for external validation purpose and to practice, sim-
plified scores were developed following the same
methodology.
The GAS scores were categorized according to the best
cutoff using preliminary remission criteria (10) as the clas-
sification variable, using the maximal sum of sensitivity
and specificity from analysis of the receiver operating
characteristic (ROC) curve at 12 months.
Sensitivity analyses explored different recall periods for
the count of the number of flares (past 3 or 6 months) and
used only the “therapeutic” criterion as the classification
rule.
In the external validation sample, Spearman’s correla-
tion coefficients between GAS score and HAQ score, phy-
sician VAS, and PASS were estimated. Analyses were
performed using Stata software package (release 11) and R
Statistical Software.
RESULTS
Delphi exercise. Twenty-six of the 30 solicited investi-
gators completed the first round of the survey, and 24 and
23 completed the second and third rounds, respectively.
After 3 rounds, 8 items (number of recent flares, VAS
pain, VAS global patient, VAS response to treatment phy-
sician, tender joint count on 68, swollen joint count on 66,
measurement of tophi, and sUA) covering 7 domains (flare
of gout, pain, PtGA, PhGA, joint inflammation, tophus
burden, and sUA) were selected to be included in the
analyses (see Supplementary Table 1, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22844/abstract).
KING data set. Baseline characteristics of the study
cohort are given in Table 1. The study flow chart in Figure
1 reports the study cohort included in these analyses.
Of the 214 subjects selected to develop the scores, 94
had a change in treatment not related to adverse events or
reductions in therapy; further, 36 subjects without a
change of treatment experienced a flare within 6 months
from baseline. As a result, 130 patients (60.7%) were clas-
sified as “active.”
The external validation sample included 61 more
patients (15 women) with a crystal-proven diagnosis of
gout and acute symptoms.
Three-step derivation. In the first step, factor analysis
using standardized variables revealed 5 components that
described the following domains: patient-reported out-
comes, joint involvement, flares, tophi burden, and serum
urate levels. These 5 factors explained 93.1% of the total
variability.
Figure 1. Study flow chart.
GAS √sUA
TJC SJC
GAS
GAS √sUA
TJC SJC
GAS
GAS √sUA
GAS
Figure 2. Formula for the calculation of different candidate gout activity scores. GAS5Gout
Activity Score; sUA5 serum uric acid (mg/dl); VAS5 visual analog scale (0–10 cm); TJC5 tender
joint count (0–68); SJC5 swollen joint count (0–66).
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In the second step, the loadings of every single factor
were used as independent variables in the linear discrimi-
nant function analysis. The linear discriminant analysis
resulted in the correct classification of 79.1% of the cases.
The discriminant function using the canonical discrimi-
nant function coefficients was used to calculate individual
scores.
In the third step, individual discriminant scores were
used as dependent variables of a hierarchical linear regres-
sion using transformed original variables as independent
variables. This model estimated the relative weights for
each variable. Bootstrap validation of these coefficients
showed absolute bias values,0.01.
Single-step derivation. Variables to be included in the
1-step process were selected on the basis of the consensus,
when the score related to the concept of disease activity
was the highest compared with scores related with disease
severity and general health.
Original variables (untransformed) were used as inde-
pendent variables in a linear discriminant function analy-
sis. The linear discriminant analysis resulted in the
correct classification of 78.5% of the cases. Cross-
validation confirmed the robustness of this finding (cross-
validated correct classification of 79.9%).
Candidate scores. After normalization of the coeffi-
cients, a first (a) and second (b) candidate activity score
for gout was constructed using both 3- and 1-step method-
ology (Figure 2). A simplified 4-variables score (c) was
also derived, selecting variables with higher contribution
to variance and easier to be measured and retrievable on
other existing data sets, and clinical practice.
Validity of candidate measures. Candidate measures
showed significant correlations with functional disability
and HRQOL, both cross-sectionally, at baseline and
Table 2. Criterion validity: cross-sectional and longitudinal correlation between gout activity scores and
functional disability or health-related quality of life*
Baseline 6 months 12 months
HAQ
SF-36
PCS
SF-36
MCS HAQ
SF-36
PCS
SF-36
MCS HAQ
SF-36
PCS
SF-36
MCS
Baseline GAS3-step-a 0.50 20.57 20.31 0.38 20.24 20.34
Baseline GAS1-step-a 0.50 20.57 20.31
6 months GAS3-step-a 0.35 20.36 20.31 0.43 20.48 20.33
6 months GAS1-step-a 0.34 20.36 20.31 0.41 20.47 20.31
12 months GAS3-step-a 0.38 20.34 20.24 0.40 20.41 20.25 0.55 20.60 20.32
12 months GAS1-step-a 0.38 20.36 20.24 0.39 20.40 20.26 0.53 20.60 20.33
Baseline GAS3-step-b 0.50 20.57 20.31
Baseline GAS1-step-b 0.50 20.57 20.30
6 months GAS3-step-b 0.35 20.36 20.31 0.42 20.48 20.33
6 months GAS1-step-b 0.35 20.36 20.30 0.41 20.46 20.32
12 months GAS3-step-b 0.38 20.34 20.24 0.41 20.40 20.25 0.54 20.59 20.33
12 months GAS1-step-b 0.39 20.37 20.23 0.39 20.40 20.27 0.53 20.59 20.33
Baseline GAS3-step-c 0.45 20.51 20.29
Baseline GAS1-step-c 0.44 20.50 20.28
6 months GAS3-step-c 0.30 20.30 20.27 0.38 20.43 20.32
6 months GAS1-step-c 0.29 20.30 20.27 0.37 20.41 20.31
12 months GAS3-step-c 0.34 20.30 20.21 0.36 20.36 20.20 0.50 20.53 20.30
12 months GAS1-step-c 0.34 20.30 20.20 0.35 20.35 20.23 0.49 20.53 20.30
* All Spearman’s rho coefficient P values, 0.001. HAQ5Health Assessment Questionnaire; SF-365Short Form 36 health
survey; PCS5physical component summary; MCS5mental component summary; GAS5Gout Activity Score.
Table 3. Discriminant validity of the Gout Activity
Scores (GAS), and single items: SMD between patients
defined as active or inactive according to internal and
external constructs*
Variable
Disease
activity
criterion
VAS
physician
(£4 vs.
>4)
Patient-
reported
remission
(GIS item)
GAS3-step-a 1.18† 1.26† 1.00†
GAS3-step-b 1.18† 1.25† 0.99†
GAS3-step-c 1.12† 1.22† 1.03†
GAS1-step-a 1.18† 1.25† 0.92†
GAS1-step-b 1.18† 1.24† 0.92†
GAS1-step-c 1.12† 1.23† 1.03†
12-month attacks 0.58† 0.69† 0.80†
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sUA
p
0.49‡ 0.57‡ 0.70‡
VAS pain 1.00† 0.92† 0.55‡
VAS patient global 0.97† 1.16† 0.77†
ﬃﬃﬃﬃﬃﬃﬃﬃ
TJC
p
0.84† 0.77† 0.27
ﬃﬃﬃﬃﬃﬃﬃﬃ
SJC
p
0.75† 0.77† 0.17
ln(11 tophi dimension) 0.49‡ 0.37§ 0.33
ln(1 1 tophi number) 0.48‡ 0.30 0.26
* SMD5 standardized mean difference; VAS5 visual analog
scale; GIS5Gout Impact Scale; sUA5 serum uric acid; TJC5
tender joint count; SJC5 swollen joint count.
† P#0.001.
‡ P#0.01.
§ P#0.05.
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followup visits (concurrent validity), and prospectively
(predictive validity) (Table 2).
Discriminant validity of the candidate scores and single
items were evaluated by the standardized mean difference
(Table 3). For all the developed instruments, composite
scores showed higher discriminatory ability when com-
pared with single variables, for every external criterion of
disease activity.
Cutoffs. Based on the operating characteristics of every
cut point, as derived from the ROC table, the cutoff associ-
ated with the lowest misclassification rate of patients in
remission, according to the definition of remission by de
Lautour et al (10), were identified for each candidate score
(Table 4).
Sensitivity analyses. In order to evaluate the robustness
of the results in a first sensitivity analysis, we varied the
timeframe for the evaluation of previous flares from 12
months to 6 months and 3 months, with no major impact
on the results (see Supplementary Tables 2–7, available
on the Arthritis Care & Research web site at http://online-
library.wiley.com/doi/10.1002/acr.22844/abstract). A sec-
ond set of sensitivity analyses was done using different
criteria for the estimation of the coefficient of the disease
activity scores using only decision to change treatment as
a criterion of disease activity, showing only a slight
increase of weighting of swollen joint (see Supplementary
Table 8, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.
22844/abstract).
External validation. Based on its metric characteristics,
the 3-step methodology showed the best results and, based
on feasibility, the 4-variable GAS (GAS-3c) score was
evaluated in the validation sample. The 4-variable GAS
score showed a significant association with the HAQ
(Spearman’s rho 0.33, P, 0.05), VAS pain (Spearman’s
rho 0.61, P,0.05), and VAS PASS (Spearman’s rho
20.37, P, 0.05).
DISCUSSION
In this article we report the development of a new com-
posite disease activity measure for gout to be used in clini-
cal practice and clinical research. We derived the gout
activity score following a data-driven methodology consis-
tent with that used for other composite measures in
rheumatic diseases and in accordance with relevant rec-
ommendations (18–21).
Disease activity has been conceptually defined as the
presence of urate tissue deposits that lead to acute arthri-
tis, which may evolve in chronic arthropathy with devel-
opment of joint damage and functional disability. This
definition is not merely focused on acute symptoms but
also on the patient-related consequences of a persistently
active disease process. The list of possible measures to be
included in the composite score derived from those whose
validity, reliability, and responsiveness were evaluated by
the OMERACT Gout Special Interest Group (22). Experts
then chose by consensus those measures that better
defined the concept of disease activity compared to other
related constructs, such as disease severity and general
health: sUA, flares, patient-reported outcomes, tophi, and
joint inflammation. The candidate items comply with the
most important ones identified by other studies, as well as
the novel definition of clinical remission for gout (3,5,10).
The most relevant difference is the inclusion of joint
inflammation and the exclusion of measures of function.
These differences might be due to the fact that items were
entirely derived from the experts and were specifically
chosen to discriminate disease activity from other con-
structs, particularly disease severity. The inclusion of an
extensive joint count might threaten the feasibility of our
instrument. Also, because of the lack of gout-specific
restricted joint count, GAS scores without joint count
were developed. In the absence of fully validated gout-
specific instruments for the evaluation of disability in
gout (23), current instruments may potentially underesti-
mate the impact of the disease on function (24). Similarly,
the clinical measurement of tophi is not the most sensitive
method available (e.g., ultrasonography, dual-energy com-
puterized tomography), but is still the most feasible in
clinical practice (13). Acute-phase reactants would be of
interest as an additional item to be included, but because
they are not routinely collected in gout databases they
were excluded.
Despite the experts having reached a consensus about
the most relevant measures to include in a composite dis-
ease activity score, this does not overcome the substantial
lack of consensus among clinicians and patients about
their relative importance, as shown by recent robust quali-
tative research (3,5). Building on these results, we applied
a methodology to weight variables, following the approach
proposed by van der Heijde et al in the first development
of the disease activity score for rheumatoid arthritis (19).
This is a data-driven approach that statistically identifies
the combination of variables and their relative weights
that best discriminate between disease states, using an
external definition of active disease. In the absence of a
gold-standard definition of active disease, by analogy from
other disease activity measures, we opted for a relevant
decision point in patient management: the moment when
the rheumatologist considered gout sufficiently active that
the patient had to start treatment with or switch to or
increase the dose of urate-lowering drugs or symptomatic
drugs. This choice reflects the perception of the physician
of a poor control of the disease process. Such a reference
standard described the real process of decision making in
Table 4. Cutoffs of clinical remission estimated at 12
months*
Score Best cutoff AUC (95% CI)
GAS3-step-a ,2.7 0.864 (0.811–0.916)
GAS3-step-b ,2.7 0.865 (0.813–0.917)
GAS3-step-c ,2.5 0.858 (0.806–0.909)
* AUC5 area under the curve; 95% CI5 95% confidence interval;
GAS5Gout Activity Score.
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practice, because the rheumatologists were unaware that
their therapeutic decisions were part of the investigation.
The choice of this classification criterion for disease activ-
ity alone would be quite arbitrary and may be associated
with a high misclassification. Alternatively, although the
occurrence of flare has a high positive predictive value
(almost 100%) in identifying active patients, all patients
with no flares in the followup might be misclassified as
“not active.” For this reason the performance of a score
developed only on the risk of flare is likely to be insuffi-
ciently accurate. Based on statistical and conceptual con-
siderations, we combined the “treatment criterion” and
“flare criterion” in order to increase the performance of
classification and to cover all the aspects of our definition
of disease activity. Sensitivity analyses support the
robustness of this approach, showing only a slight
decrease of weight for sUA and increase for joint inflam-
mation in the scores developed using only “treatment
criterion” as the classification rule.
Using the KING data set it was possible to develop the
GAS because of the prospective followup of a large num-
ber of patients, belonging to the entire spectrum of disease
and with a large number of variables prospectively collect-
ed. This is a rheumatology practice–based multicenter
cohort that ensures high reliability in the assessment but
selection of more severe or refractory disease. Of note, we
included a relatively higher proportion of men than
expected in a general population sample (25). Further val-
idation in a primary care setting is worthwhile to define
its generalizability.
We developed a first GAS, including all the relevant var-
iables. The robustness of the classification was also dem-
onstrated by the consistency of 2 different methodologies,
by internal validations, sensitivity analyses, and external
validation. Alternative scores were developed to make
variable collection and score calculations more feasible,
without major loss of discriminating ability.
A first validation of the score showed significant corre-
lation with functional disability and physical function
both cross-sectionally and longitudinally. All the scores
also perform better than single variables in discriminating
between physician- and patient-reported disease activity,
and in predicting the risk of flare throughout the followup.
Though essentially interchangeable based on the available
data, among the set of scores we developed, those follow-
ing the 3-step methodology had the best metric properties,
as also showed by the consistency of remission cutoffs.
The 4-variable (GAS3c) is the best candidate to be fully
validated and to be applied to clinical practice. The
results of the external validation confirm the same correla-
tions observed in the development sample. However,
results on the responsiveness of the different GAS will
drive a more informed choice of the best instrument.
In conclusion, we developed and validated a new
instrument to measure disease activity in gout. In practice
the gout activity score might be used to assess the disease
activity of an individual patient and determine objectively
when to modify treatment. In addition, the efficacy of ther-
apeutic strategies might be determined using an outcome
measure that incorporates relevant patient-reported
outcomes.
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